Oslo ,26 May 2023 - Following the closing of the acceptance period in the previously announced public offer,Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, will become the owner of 96.33 per cent of the share capital and votes and 93.16 per cent of the series TO 1 warrants ("Warrants") inSensidose Aktiebolag ("Sensidose ). This is an important milestone inNavamedic's plan to acquire all outstanding shares and includeSensidose's product offering in its well proven and highly scalable market access platform for healthcare products.Navamedic now plans to initiate a compulsory acquisition of the remaining shares inSensidose , and to promote a delisting of theSensidose shares and Warrants from theSpotlight Stock Market inSweden . "We are excited by the prospect of becoming the owner ofSensidose . Our next step will be to addSensidose's unique Parkinson's treatment to our existing marketing and distribution channels and rapidly ramp up commercialisation efforts in the Nordics. We have previously proven our ability to quickly improve product sales through our agile platform and know-how in the markets where we operate and have already mapped out several opportunities to increase the sales ofSensidose's treatment in some of our core markets. Moving forward, we look forward to cooperating closely withSensidose and its highly skilled team to ensure long-term success," saidKathrine Gamborg Andreassen , CEO ofNavamedic . As of the end of the acceptance period,25 May 2023 , shareholders owning 4,715,283 shares and 1,560,445 Warrants had tendered their shares and Warrants, corresponding to approximately 39.43 per cent of the share capital and votes and approximately 68.89 per cent of the Warrants inSensidose respectively.Navamedic already holds 56.90 per cent of the outstanding shares and 24.27 per cent of the Warrants in the company. The settlement of the shares and Warrants tendered in the offer is expected to commence on or around1 June 2023 .Sensidose is aSweden -based pharmaceutical company that sells drugs in combination with an innovative device for individual dosing for patients with advanced Parkinson's disease. Approximately 270 patients are being treated withSensidose's medicine inSweden ,Norway andDenmark .Sensidose has already received market approval in market approval in eight additional countries, includingFinland , whereby the company has been granted reimbursement. For further information, please contact:Kathrine Gamborg Andreassen , CEO,Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO,Navamedic Mobile: +47917 62 842 E-mail: lars.hjarrand@navamedic.com AboutNavamedic ASA Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge.Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in theUK andGreece .Navamedic is headquartered inOslo, Norway , and listed on theOslo Stock Exchange (ticker: NAVA). For more information, please visitwww.navamedic.com This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. The information was submitted for publication by CFOLars Hjarrand on26 May 2023 at 08.00 (CEST).
Click here for more information
© Oslo Bors ASA, source